Paper29099271
SOX9/miR-130a/CTR1 axis modulates DDP-resistance of cervical cancer cell.
Feng C and 10 others. Cell Cycle, 2018. Cited by 48 papers, by iCite.
Cite this record
ConductScience Library. SOX9/miR-130a/CTR1 axis modulates DDP-resistance of cervical cancer cell. Papers, record 29099271. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29099271
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cation Transport Proteins | Major topic |
| Cisplatin | Major topic |
| Drug Resistance, Neoplasm | Major topic |
| MicroRNAs | Major topic |
| SOX9 Transcription Factor | Major topic |
| 3' Untranslated Regions | |
| Antagomirs | |
| Apoptosis | |
| Cell Line, Tumor | |
| Copper Transporter 1 | |
| Female | |
| HeLa Cells | |
| Humans | |
| PTEN Phosphohydrolase | |
| Promoter Regions, Genetic | |
| Protein Binding | |
| RNA Interference | |
| RNA, Small Interfering | |
| Signal Transduction | |
| Uterine Cervical Neoplasms |
Source PubMed
References36
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27354763 | Molecular mechanisms of cisplatin resistance in cervical cancer. | Drug Des Devel Ther | 2016 | https://conductscience.org/library/papers/27354763 | PubMed |
| 2 | 20541702 | Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. | Cancer Cell | 2010 | https://conductscience.org/library/papers/20541702 | PubMed |
| 3 | 26131930 | Directional dominance on stature and cognition in diverse human populations. | Nature | 2015 | https://conductscience.org/library/papers/26131930 | PubMed |
| 4 | 22052544 | Sox9 is upstream of microRNA-140 in cartilage. | Appl Biochem Biotechnol | 2012 | https://conductscience.org/library/papers/22052544 | PubMed |
| 5 | 23137650 | Contributions of microRNA dysregulation to cisplatin resistance in adenocarcinoma cells. | Exp Cell Res | 2013 | https://conductscience.org/library/papers/23137650 | PubMed |
| 6 | 2551577 | Testicular cancer. | Curr Probl Cancer | 1989 | https://conductscience.org/library/papers/2551577 | PubMed |
| 7 | 22624711 | Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. | Cancer Cell | 2012 | https://conductscience.org/library/papers/22624711 | PubMed |
| 8 | 6370067 | Drugs five years later. Cisplatin. | Ann Intern Med | 1984 | https://conductscience.org/library/papers/6370067 | PubMed |
| 9 | 22725681 | Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese non-small cell lung carcinoma patients. | Clin Exp Pharmacol Physiol | 2012 | https://conductscience.org/library/papers/22725681 | PubMed |
| 10 | 21489289 | The functional role of long non-coding RNA in human carcinomas. | Mol Cancer | 2011 | https://conductscience.org/library/papers/21489289 | PubMed |
| 11 | 27973410 | Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs. | Int J Mol Sci | 2016 | https://conductscience.org/library/papers/27973410 | PubMed |
| 12 | 28273813 | Influence of microRNAs and Long Non-Coding RNAs in Cancer Chemoresistance. | Genes (Basel) | 2017 | https://conductscience.org/library/papers/28273813 | PubMed |
| 13 | 26878385 | mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance. | Expert Opin Ther Targets | 2016 | https://conductscience.org/library/papers/26878385 | PubMed |
| 14 | 26885752 | SOX9 indirectly regulates CEACAM1 expression and immune resistance in melanoma cells. | Oncotarget | 2016 | https://conductscience.org/library/papers/26885752 | PubMed |
| 15 | 24403515 | Membrane transporters as mediators of cisplatin side-effects. | Anticancer Res | 2014 | https://conductscience.org/library/papers/24403515 | PubMed |
| 16 | 27040383 | Nuclear factor-κB-dependent microRNA-130a upregulation promotes cervical cancer cell growth by targeting phosphatase and tensin homolog. | Arch Biochem Biophys | 2016 | https://conductscience.org/library/papers/27040383 | PubMed |
| 17 | 21823020 | TLR9 expression and its role in chemosensitivity to DDP in human cervical cancer cells in vitro. | J Huazhong Univ Sci Technolog Med Sci | 2011 | https://conductscience.org/library/papers/21823020 | PubMed |
| 18 | 26115978 | The efficacy and safety of neoadjuvant chemotherapy in the treatment of locally advanced cervical cancer: A randomized multicenter study. | Gynecol Oncol | 2016 | https://conductscience.org/library/papers/26115978 | PubMed |
| 19 | 25491626 | The role of raltitrexed/cisplatin with concurrent radiation therapy in treating advanced cervical cancer. | Eur Rev Med Pharmacol Sci | 2014 | https://conductscience.org/library/papers/25491626 | PubMed |
| 20 | 24874729 | Systems biology of cisplatin resistance: past, present and future. | Cell Death Dis | 2014 | https://conductscience.org/library/papers/24874729 | PubMed |
Cited by33
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 48 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42766055 | Therapy resistance-related ncRNAs in cervical cancer: biomarkers and therapeutic targets. | Daru | 2026 | https://conductscience.org/library/papers/42766055 | PubMed |
| 40583066 | Pattern of SOX9 expression in pleomorphic adenoma, carcinoma ex pleomorphic adenoma, and matrix-producing metaplastic carcinoma of the breast lends support to common biology. | Virchows Arch | 2025 | https://conductscience.org/library/papers/40583066 | PubMed |
| 40392306 | The SOX gene superfamily in oncogenesis: unraveling links to ncRNAs, key pathways, chemoresistance, and gene editing approaches. | Naunyn Schmiedebergs Arch Pharmacol | 2025 | https://conductscience.org/library/papers/40392306 | PubMed |
| 39659361 | Novel insights into cuproptosis inducers and inhibitors. | Front Mol Biosci | 2024 | https://conductscience.org/library/papers/39659361 | PubMed |
| 39544714 | Role of SLC31A1 in prognosis and immune infiltration in breast cancer: a novel insight. | Int J Clin Exp Pathol | 2024 | https://conductscience.org/library/papers/39544714 | PubMed |
| 39448672 | Identification of SLC31A1 as a prognostic biomarker and a target for therapeutics in breast cancer. | Sci Rep | 2024 | https://conductscience.org/library/papers/39448672 | PubMed |
| 39337406 | Micro- and Macronutrients in Endometrial Cancer-From Metallomic Analysis to Improvements in Treatment Strategies. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39337406 | PubMed |
| 39263322 | Understanding the role of miRNAs in cervical cancer pathogenesis and therapeutic responses. | Front Cell Dev Biol | 2024 | https://conductscience.org/library/papers/39263322 | PubMed |
| 37107173 | SDNOR, a Novel Antioxidative lncRNA, Is Essential for Maintaining the Normal State and Function of Porcine Follicular Granulosa Cells. | Antioxidants (Basel) | 2023 | https://conductscience.org/library/papers/37107173 | PubMed |
| 36995552 | NGS-based profiling identifies miRNAs and pathways dysregulated in cisplatin-resistant esophageal cancer cells. | Funct Integr Genomics | 2023 | https://conductscience.org/library/papers/36995552 | PubMed |
| 36984544 | Ovarian Cancer-Insights into Platinum Resistance and Overcoming It. | Medicina (Kaunas) | 2023 | https://conductscience.org/library/papers/36984544 | PubMed |
| 36776364 | p53 inhibits CTR1-mediated cisplatin absorption by suppressing SP1 nuclear translocation in osteosarcoma. | Front Oncol | 2022 | https://conductscience.org/library/papers/36776364 | PubMed |
| 36003340 | Prognostic value of SOX9 in cervical cancer: Bioinformatics and experimental approaches. | Front Genet | 2022 | https://conductscience.org/library/papers/36003340 | PubMed |
| 35138470 | SOX9/MKLN1-AS Axis Induces Hepatocellular Carcinoma Proliferation and Epithelial-Mesenchymal Transition. | Biochem Genet | 2022 | https://conductscience.org/library/papers/35138470 | PubMed |
| 35113247 | Molecular mechanisms associated with chemoresistance in esophageal cancer. | Cell Mol Life Sci | 2022 | https://conductscience.org/library/papers/35113247 | PubMed |
| 35083143 | The Role of the SOX9/lncRNA ANXA2P2/miR-361-3p/SOX9 Regulatory Loop in Cervical Cancer Cell Growth and Resistance to Cisplatin. | Front Oncol | 2021 | https://conductscience.org/library/papers/35083143 | PubMed |
| 34881182 | SOX9: Advances in Gynecological Malignancies. | Front Oncol | 2021 | https://conductscience.org/library/papers/34881182 | PubMed |
| 34453645 | Cervical cancer development, chemoresistance, and therapy: a snapshot of involvement of microRNA. | Mol Cell Biochem | 2021 | https://conductscience.org/library/papers/34453645 | PubMed |
| 33926008 | PARP1-Inhibition Sensitizes Cervical Cancer Cell Lines for Chemoradiation and Thermoradiation. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/33926008 | PubMed |
| 33868274 | Double Insurance for OC: miRNA-Mediated Platinum Resistance and Immune Escape. | Front Immunol | 2021 | https://conductscience.org/library/papers/33868274 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| MIR130A | 406919 | PubTator's text mining | https://conductscience.org/library/genes/406919 | NCBI Gene |
| PTEN | 5728 | PubTator's text mining | https://conductscience.org/library/genes/5728 | NCBI Gene |
| SLC31A1 | 1317 | PubTator's text mining | https://conductscience.org/library/genes/1317 | NCBI Gene |
| SOX9 | 6662 | PubTator's text mining | https://conductscience.org/library/genes/6662 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29099271
GET https://conductscience.org/api/papers/v1/29099271/references?page=2